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144Objective: To examine the likelihood of mitral valve repair among dialysis patients and the influence of mitral
procedure selection on surgical outcomes in this cohort.
Methods:Among patients undergoing isolated primary mitral valve surgery in the Society of Thoracic Surgeons
Adult Cardiac Surgery Database (2002-2010), we used logistic regression models to evaluate the following:
(1) the likelihood of attempted and successful mitral repair among dialysis patients (2008-2010), and (2) the
impact of mitral procedural selection on surgical mortality and composite mortality/major morbidity
experienced by dialysis patients (2002-2010). Patients with endocarditis and those undergoing emergent or
major concomitant surgeries were excluded.
Results: The study cohort consisted of 86,563 patients, of whom 1480 (1.7%) required preoperative dialysis.
Dialysis patients had a high comorbid burden, including a high prevalence of congestive heart failure, stroke,
diabetes, peripheral vascular disease, chronic obstructive pulmonary disease, and prior myocardial infarction.
Dialysis-dependent patients had a lower propensity for mitral repair (44.6% vs 61.5%; P ¼ .0010; adjusted
odds ratio [OR], 0.69; 95% confidence interval [CI], 0.61-0.78); although the odds of successful repair
(when attempted) were similar for dialysis versus nondialysis patients (OR, 0.87; 95% CI, 0.65-1.17).
Compared with nondialysis patients, dialysis patients experienced a higher mortality rate (9.3% vs 2.3%;
P< .0001; adjusted OR, 3.91; 95% CI, 3.17-4.81) and composite mortality or major morbidity (40.9% vs
15.9%; P<.0001; adjusted OR, 2.72; 95% CI, 2.41-3.07); however, adjustment for procedure selection did
not substantially attenuate this effect (2.3% and 2.1% change-in-estimate for mortality and composite
mortality/major morbidity, respectively).
Conclusions: Dialysis patients undergo mitral repair less frequently, although repair success is equally likely
when attempted among dialysis versus nondialysis patients. Dialysis-dependent renal failure is associated
strongly with early mortality and major morbidity. However, procedure selection (repair vs replacement)
does not appear to have a clinically meaningful impact on these short-term outcomes. (J Thorac Cardiovasc
Surg 2014;148:144-50)Supplemental material is available online.
The prevalence of end-stage renal disease (ESRD) has
continued to increase over the past decade.1 In the field of
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The Journal of Thoracic and Cardiovascular Surgchallenge. Despite recent advances in perioperative cardio-
vascular care, postoperative outcomes among ESRD
patients remain poor.2 In addition, long-term survival after
valve surgery was limited in this cohort.2,3
Surgical management of valvular heart disease in ESRD
patients is based on limited data. Although mitral valve
repair has gained increasing acceptance as the procedure
of choice for correction of mitral valve pathology, the
superiority of mitral valve repair over replacement among
ESRD patients has not been established. In addition, the
optimal choice of prosthesis remains controversial, with
recent reports of equivalent survival of those treated with
mechanical versus bioprosthetic valves.3,4
In this study, we sought to accomplish the following:
(1) to describe current trends in the treatment of mitral valve
disease among patients with ESRD, (2) to evaluate the like-
lihood of repair (vs replacement) in ESRD (vs non-ESRD)
patients, (3) to examine the likelihood of successful repair
among ESRD patients in whom a mitral valve repair was
attempted, and (4) to determine the degree to which earlyery c July 2014
Abbreviations and Acronyms
ACSD ¼ Adult Cardiac Surgery Database
CHF ¼ congestive heart failure
CI ¼ confidence interval
ESRD ¼ end-stage renal disease
OR ¼ odds ratio
STS ¼ Society of Thoracic Surgeons
Vassileva et al Acquired Cardiovascular Diseasepostoperative outcomes were influenced by mitral valve
treatment strategy (repair vs replacement). To answer these
questions, we evaluated data for mitral valve operations
performed in the Society of Thoracic Surgeons Adult
Cardiac Surgery Database (STS ACSD) hospital network
between 2002 and 2010.A
C
DMETHODS
Data Source
The STS ACSD is the world’s largest cardiac surgical database,
developed as a platform for quality assurance and improvement initiatives,
including more than 1000 hospital centers throughout North America. The
data are subject to rigorous quality checks, with more than 96% agreement
between submitted data and that observed through direct chart review.5
Patient Population
The study cohort consisted of all patients who underwent primary
isolated mitral valve surgery with or without concomitant tricuspid valve
surgery, surgery for atrial fibrillation, or atrial septal defect/patent foramen
ovale closure from January 1, 2002, through December 31, 2010. Patients
with endocarditis, prior cardiac surgery, concomitant coronary artery bypass
graft or other valvular surgery (except tricuspid), emergent/salvage/missing
status, cardiogenic shock, resuscitation, cardiac trauma, cardiac transplant,
concomitant carotid, vascular, or thoracic procedures were excluded from
the analysis (Figure 1). Beginning in 2008, the STS ACSD data collection
form (version 2.62) included whether a mitral valve repair was attempted
in patients who received mitral valve replacement (ie, unsuccessful repair).
As such, evaluation of the likelihood for successful repair (among those in
whom mitral valve repair was attempted) was evaluated in a subgroup of
patients treated from January 1, 2008, through December 31, 2010. The
Duke University School of Medicine Institutional Review Board granted
a waiver of informed consent and authorization for this study.
Data Definitions and Study End Points
The STS ACSD collects detailed information on baseline patient
characteristics, surgical details, inpatient morbidity, and surgical mortality.
Detailed definitions for data elements are available on the STS web site
(www.sts.org). Surgical mortality was defined as death during the index
hospitalization or within 30 days, whichever was longer. Composite major
morbidity or mortality was defined as the occurrence of any of the
following end points: surgical mortality, postoperative stroke, prolonged
ventilation (>24 hours), deep sternal wound infection, and reoperation
for any reason. Attempted mitral repair was defined as any surgery that
included an attempted repair (successful or unsuccessful) of the mitral
valve. Successful repair meant that the patient left the operating room
with repair. Unsuccessful repair was defined as an intraoperative conver-
sion to mitral valve replacement. For the purposes of risk-adjustment
models, continuous variables were treated according to the standards
established for the STS ACSD valve models,6 with the exception of
ejection fraction, which was truncated at 60% (rather than 50%, as inThe Journal of Thoracic and Cathe valve model) to account for the important distinction between normal
and abnormal ejection fractions in patients with mitral valve pathology.
In addition, we included surgical year as a covariate in the mortality and
mortality/morbidity models. The study end points were treatment received,
mortality, and a composite of major morbidity and mortality.
Statistical Analysis
Patient characteristics. Descriptive statistics were based on
nonmissing values and were presented as median and interquartile range
(25th-75th percentile) for continuous variables or frequency and
percentage for categoric variables. The Wilcoxon rank sum test was
used to compare the distribution of continuous variables, whereas the
Mantel-Haenszel test was used for categoric variable comparisons.Missing
data were rare (<0.5% for all variables). Missing values of body surface
area and body mass index were imputed to sex-specific median values.
Missing values of ejection fraction were imputed to sex-specific median
values for patients with known congestive heart failure (CHF) and to
50% for those without CHF. Missing values of the remaining risk factors
were imputed to the most common value.
Temporal trends in the treatment of mitral valve patho-
logy. From 2002 to 2010, the proportion of mitral valve operations that
included a successful mitral valve repair was calculated for the overall
cohort and separately among dialysis and nondialysis patients. Temporal
trends in the proportion of mitral valve repair procedures then were
compared among dialysis and nondialysis patients. Likewise, the
proportion of mitral valve replacement procedures that included the use
of a bioprosthesis was calculated in the overall cohort and among patients
with and without dialysis during this interval. Temporal trends in the use of
bioprosthetic valves were compared across dialysis and nondialysis pa-
tients. Cochran-Armitage tests were used to test for trends across the years.
Likelihood of attempted and successful mitral valve
repair. To model the odds of an attempted mitral valve repair procedure
among dialysis versus nondialysis patients, a logistic regression model was
fit with attempted repair as the outcome of interest. Preoperative dialysis
(yes/no) was included as the exposure of interest and all variables from
the STS ACSD mitral valve perioperative risk of mortality model were
included as covariates.11 To assess the odds of a successful repair, a similar
model was fit among the subgroup of patients for whom a mitral valve
repair was attempted. To account for clustering of patients within hospitals,
we used generalized estimating equations for each of these models.7
Association with outcomes. To evaluate the association between
preoperative dialysis status (yes/no) and outcomes (mortality and
composite mortality or major morbidity) logistic regression models were
fit using a generalized estimating equations approach and included all
variables from the ACSD mitral valve perioperative risk of mortality
models. To further evaluate the effect of treatment received (repair or
replacement) on the primary association of interest, a treatment indicator
subsequently was included in each of the logistic regression models. A
change-in-estimate approach was used to evaluate whether treatment
received (repair vs replacement) had a meaningful effect on the association
between preoperative dialysis status and outcomes. Using established
standards, a clinically meaningful change-in-estimate was defined a priori
as a 10% or greater change in the primary risk-adjusted association after
adjusting for the treatment received.8
SAS statistical software (version 9.1; SAS Institute, Cary, NC) was used
for all calculations.
RESULTS
Patient Characteristics
Baseline characteristics of dialysis and nondialysis
patients are shown in Table 1. Compared with nondialysis
patients, those with preoperative dialysis were youngerrdiovascular Surgery c Volume 148, Number 1 145
All patients who had MV surgery (2002-2010) 
n=908,013 
Patients with missing gender or age 
n=278 
Patients remaining after exclusion of those with 
missing gender/age 
n=907,735 
Patients remaining after exclusion of those with 
reoperation 
n=790,579 
Patients with reoperation or 
previous cardiac procedure 
n=117,156
Patients remaining after exclusion of those 
because of status 
n=754,559 
Patients with emergent/emergent 
salvage/missing status 
n=36,020 
Patients remaining after exclusion of 
shock/resuscitation 
n=745,217 
Patients with cardiogenic 
shock/resuscitation 
n=9,342 
Patients with concomitant 
procedures 
n=650,519 
Patients remaining after concomitant procedures 
n=94,698 
Patients with endocarditis 
n=8,135 
Final patient sample for analysis 
n=86,563 
FIGURE 1. Flow chart of the study population included in the analysis. MV, Mitral valve.
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D(median age, 55 vs 63 y; P< .0001), more often female
(61.8% vs 52.3%; P < .0001), or African American
(44% vs 9.2%; P<.0001). As expected, dialysis patients
had a higher burden of comorbidities, including diabetes,
peripheral vascular disease, stroke, chronic lung disease,
history of prior myocardial infarction, and CHF. Pre-
operative atrial fibrillation was less common in the dialysis
group. Median ejection fraction for dialysis patients was
lower than for nondialysis patients (50% vs 56%;
P < .0001), and there were more dialysis patients with
severe ventricular dysfunction, as well as with mild-to-
moderate ventricular dysfunction.
Valve pathology and surgical characteristics are pre-
sented in Table 2. Mitral stenosis was more common among
dialysis (vs nondialysis) patients (20.6% vs 15.2%;
P ¼ .0001). Although we excluded emergent operations
from our study, 36.0% of dialysis patients underwent an
urgent surgery compared with 19.3% of the nondialysis
patients (P<.0001). Repair rates were significantly lower
for dialysis patients (44.6% vs 61.5%; P ¼ .0010). Among146 The Journal of Thoracic and Cardiovascular Surgdialysis (vs nondialysis) patients, a larger proportion of
mitral repairs consisted of an isolated mitral annuloplasty,
whereas the majority of mitral repairs among nondialysis
patients included mitral valve reconstruction in conjunction
with annuloplasty. Mechanical valve implantation
comprised 41.7% of valve replacements in nondialysis
patients compared with 45.9% in dialysis patients
(P ¼ .0351). Dialysis patients more often underwent a
concomitant tricuspid procedure. Cardiopulmonary bypass
and cross-clamp times were similar between the 2 groups.
Temporal Trends in Surgical Treatment Strategies
for Mitral Valve Disease
From 2002 to 2010, rates of successful mitral repair
increased from 52.4% to 65.7% in the overall cohort
(P<.0001; Figure 2, A). There was a trend of increasing
mitral repair rates over time for nondialysis patients
(P<.0001); however, among dialysis patients, no signifi-
cant trend was noted over time (P ¼ .2). Repair rates for
dialysis patients remained lower than those for nondialysisery c July 2014
TABLE 1. Comparison of patient characteristics between dialysis and
nondialysis patients undergoing isolated primary mitral valve surgery
in the STS database from 2002 through 2010
Variable*
Overall
(n ¼ 86,563)
No dialysis
(n ¼ 85,083)
Dialysis
(n ¼ 1480)
P
valuey
Median age (y)
(IQR)z
62 (52-72) 63 (52-72) 55 (45-65) <.0001
Female 52.5 52.3 61.8 <.0001
Caucasian 83.8 84.5 42.5 <.0001
Diabetes 12.4 12.1 31.3 <.0001
Chronic lung disease 19.4 19.3 29.6 <.0001
Peripheral vascular
disease
4.0 3.8 13.3 <.0001
Stroke 4.6 4.5 8.9 <.0001
CHF 45.5 45.1 71.0 <.0001
CHF and NYHA
class IV
8.7 8.5 21.3 <.0001
Preoperative IABP
or inotropes
2.5 2.4 3.5 .2459
Atrial fibrillation 31.8 32.0 20.7 <.0001
Previous MI 5.8 5.7 12.5 <.0001
Median ejection
fraction (IQR)z
56 (50-60) 56 (50-60) 50 (40-60) <.0001
<35 6.7 6.6 13.6 <.0001
35 and<50 15.1 14.9 26.4
50 78.2 78.5 60.0
IQR, Interquartile range; NYHA, New York Heart Association; IABP, intra-aortic
balloon pump; MI, myocardial infarction; CHF, congestive heart failure. *Indicates
percentage unless otherwise specified. yAll tests are adjusted for confounding by
participant. P values are based on stratum-adjusted Pearson chi-square tests for all
categoric row variables. zP values are based on stratum-adjusted chi-square
rank-based group means score statistics for all continuous/ordinal row variables.
This is equivalent to stratum-adjusted Wilcoxon tests.
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Dpatients throughout the study period (51.1% vs 65.9% in
2010). The overall use of bioprostheses for mitral replace-
ment increased from 42.2% in 2002 to 68.2% in 2010
(P< .0001), a trend that was true for both dialysis and
nondialysis patients (Figure 2, B).Likelihood for Attempted and Successful Mitral
Valve Repair
After adjustment for baseline characteristics, dialysis
patients had a lower odds of undergoing mitral valve repair
than nondialysis patients (OR, 0.69; 95% CI, 0.61-0.78).
In addition, dialysis patients were less likely to have an
attempted mitral repair (OR, 0.62; 95% CI, 0.52-0.73).
However, among patients in whom a mitral valve repair
was attempted, those on dialysis had a similar odds of suc-
cess as nondialysis patients (OR, 0.87; 95% CI, 0.65-1.17).Effect of Treatment Received (Repair Versus
Replacement) on the Adjusted Association Between
Dialysis Status and Early Outcomes (Mortality, and
Composite Mortality and Major Morbidity)
Unadjusted mortality and postoperative morbidities are
shown in Table 3. Surgical mortality was significantlyThe Journal of Thoracic and Cahigher for dialysis patients (9.3% vs 2.3%; P<.0001), as
was the composite of major morbidity and mortality
(40.9% vs 15.9%; P<.0001). All complications examined
occurred more frequently in the dialysis population. These
included prolonged ventilation, reoperation for bleeding,
permanent stroke, atrial fibrillation, deep sternal wound
infection, transfusion, and pneumonia. As expected, length
of stay also was longer for the dialysis patients (median
length of stay, 9 vs 6 days; P<.0001).
After adjustment for baseline characteristics, dialysis
patients had nearly 4-fold higher surgical mortality than
nondialysis patients (OR, 3.91; 95% CI, 3.17-4.81). After
accounting for mitral procedure selection (repair vs replace-
ment), the primary association between dialysis status and
adjusted surgical mortality remained similar (OR, 3.82;
95% CI, 3.09-4.71; change-in-estimate, 2.3%).
After adjustment for baseline characteristics, dialysis
patients had more than 2-fold higher composite mortality
and morbidity than nondialysis patients (OR, 2.72; 95%
CI, 2.41-3.067). After adjusting for mitral procedure
selection (repair vs replacement), this association remained
similar (OR, 2.66; 95% CI, 2.36-3.00; change-in-estimate,
2.1%).
DISCUSSION
In this article, we evaluated the impact of mitral
procedure selection on the outcomes of dialysis patients
undergoing mitral valve surgery in the United States. There
were several noteworthy findings of our research. The
analyses, based on data from the STS ACSD, represent
the largest study on mitral valve surgery in the ESRD
population. We found that dialysis patients receive mitral
repair less frequently, compared with nondialysis patients.
In contrast to nondialysis patients, mitral repair rates
are not increasing over time among dialysis patients.
Furthermore, dialysis patients undergo attempted repair
less frequently. Our study cannot answer the question of
whether these findings are the result of treatment bias.
Disparities of treatment selection have been reported
previously for a number of patient populations, so this
possibility exists.9,10 However, other more plausible
explanations are likely. Differences in valve morphology
may dissuade repair attempt. Patients on dialysis often
have heavy annular and leaflet calcifications, which may
limit repair success. It appears, however, that surgical
judgment remains of paramount importance. Of those
dialysis patients in whom repair was attempted, the odds
of success were similar to those in the nondialysis
population.
Adjusted mortality for dialysis patients undergoing
mitral valve surgery remains almost 4-fold higher than
for their nondialysis counterparts. In contrast to the
well-documented benefit of mitral valve repair on early
outcomes among nondialysis patients, we found nordiovascular Surgery c Volume 148, Number 1 147
TABLE 2. Surgical characteristics between dialysis and nondialysis patients undergoing isolated primarymitral valve surgery in the STS database
from 2002 through 2010
Variable* Overall (n ¼ 86,563) No dialysis (n ¼ 85,083) Dialysis (n ¼ 1480) P valuey
Elective status 80.5 80.7 64.1 <.0001
Mitral stenosis 15.3 15.2 20.6 .0001
Median CPB time (min) (IQR) 115 (89-149) 115 (89-149) 116 (90-148) .8691
Median aortic cross-clamp time (min) (IQR) 84 (64-110) 84 (64-111) 80 (62-107) .0143
Mitral repair 61.2 61.5 44.6 <.0001
Attempted MV repair (denominator - MV replacementz) 5.6 5.7 4.8 .1848
MV repair procedure (denominator - MV repairx) <.0001
Annuloplasty only 31.1 30.8 57.1
Reconstruction with annuloplasty 66.7 67.0 39.2
Reconstruction without annuloplasty 2.2 2.2 3.6
Tricuspid procedure <.0001
Repair 11.3 11.1 22.3
Replacement 0.4 0.4 1.3
Tricuspid repair procedure (denominator–TV repairjj)
Annuloplasty only 75.5 75.5 74.2 .6921
Reconstruction with annuloplasty 18.2 18.2 20.1
Reconstruction without annuloplasty 6.3 6.3 5.8
Mechanical prosthesis (denominator - MV replacement{) 41.8 41.7 45.9 .0351
P values are based on stratum-adjusted chi-square rank-based group means score statistics for all continuous/ordinal row variables. This is equivalent to stratum-adjusted
Wilcoxon tests. CPB, Cardiopulmonary bypass; IQR, interquartile range; MV, mitral valve; TV, tricuspid valve. *Indicates percentage unless otherwise specified. yP values
are based on stratum-adjusted Pearson chi-square tests for all categoric row variables. zIndicates the percentage of attempted mitral repairs in patients undergoing MV
replacement. xIndicates the percentages within the subset of patients undergoing MV repair. jjIndicates the percentages within the subset of patients undergoing TV replacement.
{Indicates the percentage of mechanical prostheses in the subset of patients undergoing MV replacement.
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Devidence that treatment selection impacts surgical outcomes
among dialysis patients. Because dialysis remains such a
strong predictor of mortality and major morbidity,
procedure selection (mitral repair vs replacement) does
not appear to have a significant impact on the disparity
in mortality and major morbidity between dialysis and
nondialysis patients.
There are other additional benefits of mitral repair
beyond improved survival that may be particularly relevant
to the ESRD patient population. The choice of prosthesis for
valve replacement has been studied extensively and
although survival is equivalent for dialysis patients under-
going mechanical versus bioprosthetic valve replacement,
it appears that bioprostheses are associated with fewer
valve-related complications.3,11-13 The difficulty in
maintaining a target anticoagulation level in dialysis
patients and the platelet dysfunction associated with
ESRD makes the use of mechanical prostheses a less
attractive option because it increases the risk of
thromboembolic and/or bleeding complications. This has
been documented in the literature and likely explains the
trend that we found of increasing use of bioprosthetic
replacement in these patients over time. On the other
hand, early degeneration of bioprosthetic valves in the
dialysis population has been reported previously.14 More
recent reports have questioned those conclusions.3,12,15
Nevertheless, these counterpoints were made from
retrospective reports based on data from patients who
presented for reoperation. Prospective echocardiographic148 The Journal of Thoracic and Cardiovascular Surgfollow-up evaluation of ESRD patients with bioprosthetic
valves to study the true incidence of bioprosthetic valve
failure are lacking.
The poor long-term survival notwithstanding, cardiac
disease remains the most important cause of death in this
patient population. Aberrant calcium homeostasis, often
exacerbated by secondary hyperparathyroidism, which
frequently is seen in these patients, indeed may contribute
to early prosthetic valve calcification, which may be
under-represented in the published literature of retrospec-
tive reports on patients deemed suitable for referral for
reoperation.16 In addition, the logic that a patient is not
likely to outlive a bioprostheses may be less valid for
potential transplant candidates, in view of the fact that renal
transplantation has been shown to increase survival in this
patient cohort.17 Although there may be reluctance to refer
patients with cardiac disease for renal transplantation,17 the
best outcomes of dialysis patients are seen if they
subsequently undergo renal transplantation. For example,
Bechtel et al17 found that 5-year survival for dialysis
patients undergoing cardiac surgery was 93.8% if they
subsequently underwent transplantation compared with
39.4% if they did not (P ¼ .0001). Therefore, although
the choice of mitral procedure in dialysis patients remains
a challenging issue, some of the long-term drawbacks of
prosthetic valve replacement make mitral valve repair an
attractive option, if feasible.
Although we did not find a profound positive impact of
mitral repair compared with replacement in patients onery c July 2014
FIGURE 2. Trends in mitral repair rates and prosthesis choice for mitral replacement for dialysis versus nondialysis patients from 2002 through 2010 in the
STS database. A, Trends in mitral repair rates. B, Trends in prosthesis choice for mitral replacement. MV, Mitral valve.
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Ddialysis with respect to major morbidity and early mortality,
there aremany other potential benefits ofmitral repair in this
population. Because the STS database lacks follow-up
information, the effect of mitral procedure selection of the
ventricular function in the dialysis subset could not be
evaluated. Ample literature has been reported on theTABLE 3. Postoperative mortality and major morbidity of dialysis and no
the STS database from 2002 through 2010
Variable* Overall (n ¼ 86,563)
Median ventilation time (h) (IQR)z 7.5 (4.6-14.9)
Prolonged ventilation time (h) 11.0
Permanent stroke 1.4
Atrial fibrillation 21.1
Reoperation for bleeding 3.8
Deep sternal wound infection 0.2
Blood product usex 52.4
Pneumonia 2.9
Any complication 44.0
Median LOS (d) (IQR)* 6 (5-9)
Surgical mortality (%) 2.4
Composite morbidity and mortality (%) 16.3
LOS, Length of stay; IQR, interquartile range. *Indicates percentage unless otherwise speci
row variables. zP values are based on stratum-adjusted chi-square rank-based group m
stratum-adjusted Wilcoxon tests. xIntraoperatively or postoperatively.
The Journal of Thoracic and Caimproved ventricular function with mitral repair as opposed
to replacement, and we speculate that these findings can be
applied safely to patients on dialysis as well. In addition,
dialysis patients who are subjected to frequent vascular
access encounters are at increased risk of infective
endocarditis. The lower risk of endocarditis associatedndialysis patients undergoing isolated primary mitral valve surgery in
No dialysis (n ¼ 85,083) Dialysis (n ¼ 1480) P valuey
7.4 (4.6-14.5) 17.1 (7.6-38.5) <.0001
10.6 35.0 <.0001
1.4 2.7 <.0001
21.1 24.0 .0068
3.8 5.5 .0153
0.2 0.9 <.0001
52.0 81.8 <.0001
2.8 6.0 <.0001
43.7 62.4 <.0001
6 (5-9) 9 (7-14) <.0001
2.3 9.3 <.0001
15.9 40.9 <.0001
fied. yP values are based on stratum-adjusted Pearson chi-square tests for all categoric
eans score statistics for all continuous/ordinal row variables. This is equivalent to
rdiovascular Surgery c Volume 148, Number 1 149
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Dwith mitral valve repair may justify pursuing repair in this
patient subset.
Our study had some limitations. It was an observational
study with all of the biases inherent in this type of study
design. Our comparison was limited by the profound
differences in demographics and comorbidities between
the dialysis and nondialysis patients undergoing mitral
valve surgery. Although adjusted analyses attempt to
account for these differences, it is possible that additional
factors not accounted for may be confounders. For example,
the etiology of renal failure (ie, primary vs secondary; eg, to
diabetic or hypertensive nephropathy), has been found to
affect outcomes in heart valve replacement surgery.15
Diabetic etiology is a more powerful predictor of death
than hypertension or other causes.3,17-19 Information on
the etiology of ESRD was not available in the STS
database. In addition, the duration of dialysis at the time
of surgery was unknown. In the study period chosen,
detailed information on valve morphology, including
degree of leaflet calcification, which is common in these
patients, was not available but may have been helpful to
evaluate the proportion of potentially repairable valves in
which repair was not attempted.
Similar to any outcomes study, our study aimed to identify
an area in need of improvement, in this case in cardiac valve
surgery among dialysis patients. The increasing incidence of
ESRD in the United States and the high prevalence of car-
diac disease, including valve disease in this population,20
make efforts to improve the outcomes of patients in ESRD
undergoing valve surgery particularly relevant. There are
several points to consider. Perhaps prosthesis choice should
be made with consideration for suitability for renal trans-
plant. Furthermore, at the end of the cardiac surgical care
episode, a statement of whether the patient now may be
suitable for renal transplant from a cardiac standpoint may
be valuable to the further care of dialysis patients. Initiatives
to decrease transfusion rates in ESRDpatients (81.8% in our
study of patients undergoing mitral valve surgery) may be
beneficial. Serial echocardiographic follow-up studies on
dialysis patients with bioprosthetic valves would be helpful.
Last, mitral repair remains an attractive option for the
treatment of mitral valve disease despite an apparent lack
of short-term mortality benefit in the dialysis subset. The
effect of mitral repair on the long-term survival in this
patient subset needs further study.
In conclusion, dialysis remains such a strong predictor of
mortality and major morbidity in mitral valve surgery that
procedure selection (repair vs replacement) does not appear
to have a clinically meaningful impact on the disparity in
mortality and major morbidity between dialysis and
nondialysis patients. Dialysis patients undergo mitral repair
less frequently, although in those in whom repair is
attempted, the success rate is equivalent to that of non-
dialysis patients. Despite the lack of profound short-term150 The Journal of Thoracic and Cardiovascular Surgmortality benefit associated with mitral repair in
dialysis patients and taking into account solid surgical
judgment for valve repair suitability, other factors
including challenges in prosthesis choice selection for valve
replacement, transplantation suitability, and patient risk for
endocarditis may make mitral valve repair in dialysis
patients an attractive option.
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SUPPLEMENTARY TABLE E1. ORs for procedure selection
Variable P value Odds ratio
Dialysis <.0001 0.692
Afib <.0001 0.814
Linear age knot at 50 <.0001 0.992
Linear age knot at 75 <.0001 0.972
Linear BSA <.0001 2.658
Quadratic BSA <.0001 0.26
CHF but NYHA not equal to class 4 vs no CHF <.0001 0.808
CHF and NYHA equal to class 4 vs no CHF <.0001 0.735
Chronic lung disease <.0001 0.888
Creatinine level <.0001 0.829
CVD but no CVA vs no CVD <.0001 0.82
CVD and CVA vs no CVD <.0001 0.773
Diabetes: noninsulin vs no diabetes <.0001 0.83
Diabetes: insulin vs no diabetes .0090 0.894
Ejection fraction <.0001 1.012
Female vs male <.0001 0.718
Interaction between female and linear BSA <.0001 0.358
Interaction between female and quadratic BSA .0070 1.936
Hypertension .1987 0.981
IABP inotrope .1520 0.934
Immune-suppressive treatment <.0001 0.79
Mitral insufficiency <.0001 1.677
Tricuspid insufficiency .1328 0.966
Left main disease .6802 1.055
MI within 21 d <.0001 0.67
Disease vessel number .1303 0.95
PVD .0059 0.9
Race: black vs white and others <.0001 0.88
Hispanic vs white and others <.0001 0.736
Status: urgent vs elective <.0001 0.799
Aortic stenosis <.0001 0.56
Mitral stenosis <.0001 0.12
Unstable angina (no MI<7 d) .9579 0.997
Afib, Atrial fibrillation; BSA, body surface area; NYHA, New York Heart Association;
CVD, cardiovascular disease; CVA, cardiovascular accident; IABP, intra-aortic
balloon pump; MI, myocardial infarction; PVD, peripheral vascular disease;
CHF, congestive heart failure.
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